Hubertus von Baumbach, Boehringer Ingelheim's chairman of the board of managing directors, at its annual press conference on April 16, 2024 (Arne Dedert/picture-alliance/dpa/AP Images)
April 16, 2024 07:43 AM EDTUpdated April 30, 10:56 AM
Pharma

Cor­rec­tion: Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

Boehringer In­gel­heim put the spot­light on a pipeline ripe with mile­stones over the next decade dur­ing its full-year 2023 call with the press.

Dri­ven in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times